ILLUCCIX (gallium ga-68 gozetotide)
ILLUCCIX is indicated for the treatment of Prostate Cancer; Metastasis; Recurrence.
Details
- Status
- Prescription
- First Approved
- 2021-12-17
- Patent Cliff
- 2035
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
ILLUCCIX Approval History
What ILLUCCIX Treats
3 indicationsILLUCCIX is approved for 3 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Prostate Cancer
- Metastasis
- Recurrence
ILLUCCIX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in ILLUCCIX's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ILLUCCIX treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to ILLUCCIX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ILLUCCIX FDA Label Details
Indications & Usage
FDA Label (PDF)ILLUCCIX is indicated for the treatment of Prostate Cancer; Metastasis; Recurrence.
ILLUCCIX Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for ILLUCCIX
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2035
- • 1 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.